Brenda Gallie

Gallie completed MD at Queen’s University, Residency at the University of Toronto and post-graduate research at Memorial Sloan-Kettering Cancer Center. She developed eCancerCareRB (eCCRB) facilitating retinoblastoma clinical care at SickKids since 2001. eCCRB supports novel propensity-matching evaluation of clinical outcomes. To enhance clinical communication with patients, families, and healthcare teams independent of geography, with charity International Retinoblastoma Consortium, she developed DEPICT (Disease-specific E-Patient Illustrated Clinical Timeline) HEALTH full view for life on the Cloud.

Ultimately, with patient research consent, DEPICT point-of-care data from global Sites will be available to ethics-approved projects. Gallie led the Phase I study of sustained chemotherapy release to only the eye with retinoblastoma. Preliminary “game changing” results with novel data analysis based on eCCRB are suggested equivalent to randomization. One day, such analysis of DEPICT primary global data may address the severe inequities faced by 9,000 children diagnosed with retinoblastoma annually, responding to the challenge of the World Health Organization.

Research

To enhance clinical communication with patients, families, and healthcare teams independent of geography, with charity International Retinoblastoma Consortium, she developed DEPICT HEALTH “full view for life” on the Cloud. Ultimately, with patient research consent, DEPICT point-of-care data from global Sites will be available to ethics-approved projects. Gallie led the Phase I study of sustained chemotherapy release to only the eye with retinoblastoma. Preliminary “game changing” results with novel data analysis based on eCC^RB may to be equivalent to the global standard of randomized trial results. One day, such analysis of DEPICT primary global data may address the severe inequities faced by 9,000 children diagnosed with retinoblastoma annually, responding to the challenge of the World Health Organization. Future research will include lifelong surveillance for Subsequent Malignant Neoplasms in high risk H1 patients.  

Education and experience

• 1999–Present: Clinician Scientist, University Health Network, Toronto, Ontario, Canada
• 1999–2014: Senior Scientist, Campbell Cancer Research Institute/ Ontario Cancer Institute/ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
• 1998–1999: Director Cancer & Blood Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada
• 1994–1997: Scientific Director, The Eye Research Institute of Canada, Toronto Hospital (Western Division), Toronto, Ontario, Canada
• 1988–Present: Professor, The Departments of Ophthalmology, Molecular Genetics and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
• 1988–2000: Senior Scientist, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
• 1987–1988: Associate Professor, The Department of Medical Genetics, University of Toronto, Toronto, Ontario, Canada
• 1982–1988: Associate Professor, Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
• 1981–1990: Member, Institute of Medical Science, School of Graduate Studies, University of Toronto, Toronto, Ontario, Canada
• 1979: Ontario Cancer Treatment and Research Foundation Associate Scientist, Toronto, Ontario, Canada
• 1978–1982: Assistant Professor, Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
• 1976–Present: College of Physicians and Surgeons of Ontario, Clinical Ophthalmology, Toronto, Ontario, Canada
• 1976: Fellow of the Royal College of Physicians and Surgeons Canada, Toronto, Ontario, Canada
• 1974–1976: Research Fellow, Memorial Sloan-Kettering Cancer Center, New York City, New York, United States
• 1972: Licentiate of the Medical Council of Canada, Toronto, Ontario, Canada
• 1971–1974: Resident, Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
• 1971: Research Fellow, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
• 1970: Internship, Toronto Western Hospital, Toronto, Ontario, Canada
• 1969: Doctor of Medicine, Queen's University, Kingston, Ontario, Canada

Achievements

• 2024: Arthur W. Stickle Pediatric Ophthalmology Lecture, Washington University School of Medicine
• 2023: Paul T. Finger Guest Lecturer
• 2023: A. Linn Murphree MD Lecture, Children's Hospital of Los Angeles
• 2023: Angeline Parks Distinguished Visiting Professor, Children's National Hospital
• 2019: American Journal of Ophthalmology Lecture, Pan-American Congress of Ophthalmology
• 2019: Murphree Lecture, International Society of Ocular Oncology
• 2019: Uplifting Athletes Collaborative Leadership Award
• 2018: Helen Keller Prize for Vision Research
• 2016: Transamerica Visiting Professorship in Vision Science, University of California, San Francisco
• 2015: Dr. Mila Oh Memorial Lecture, Canadian Retina Society
• 2014: Member of the Order of Canada
• 2014: 1RBW Conference Keynote: “One Retinoblastoma World: A Consortium for Optimized Care Everywhere”
• 2014: Jack Crawford Lecture, Department of Ophthalmology & Vision Science, SickKids
• 2013: Lifetime Achievement Award, Canadian Ophthalmological Society
• 2012: Sir Norman Gregg Lecture and Medal, Australian and New Zealand College of Ophthalmology
• 2011: Biomedical Science Ambassador Award Honoree, Banting Research Foundation and Partners in Research
• 2011: Canadian Gene Cure Foundation Champion of Genetics
• 2010: Silver Fellow, ARVO Class of 2010
• 2010: Bowman Lecture and Medal, Royal College of Ophthalmologists, “Sustainable Globally Accessible Care for Retinoblastoma Families”
• 2009: Martin J. Steinbach Lectureship: “An Achievable Dream: Global Best Practices for Retinoblastoma”
• 2009: Alcon Research Institute Award
• 2008: Ellsworth Lecture, International Society of Eye Genetic Disease and Retinoblastoma
• 2007: MacDonald Prevention of Blindness Award
• 2007: Dalhousie University Distinguished Lecturer
• 2006: Member of the Order of Ontario
• 2006: POGO Companion Award, Pediatric Oncology Group of Ontario
• 2006: Claude Worth Visiting Professorship, United Kingdom
• 2006: Clair Bombier Distinguished Lecturer, School of Optometry, University of Waterloo
• 2005: John Pratt-Johnson Lecture, University of British Columbia, “The Global Retinoblastoma Citizen”
• 2005: Canadian Project Excellence Award for Social Impact (Retinoblastoma Solutions)
• 2000: Mooney Lectureship, Irish Ophthalmological Society
• 1999: O. Harold Warwick Prize, National Cancer Institute of Canada
• 1998: Doyne Memorial Lecturer, Oxford Congress
• 1997–2002: Medical Research Council of Canada Distinguished Scientist Award
• 1994: Royal College Lecturer, Canadian Ophthalmological Society
• 1991: MacDonald Prevention of Blindness Award
• 1990: Royal College of Physicians and Surgeons of Canada Gallie Lecturer
• 1987: CIL Visiting Lectureship, Lakehead University
• 1983: American Academy of Ophthalmology Honor Award
• 1979: American Society for Therapeutic Radiologists Gold Plaque for Scientific Exhibit Achievement (with Princess Margaret Hospital Group)
• 1979: Ontario Cancer Treatment and Research Foundation Associate Scientist
• 1974: University of Toronto Ophthalmology Alumni Clinical Research Prize
• 1969: Aesculapian Society Award
• 1969: Professor's Prize in Ophthalmology, Queen's University

1. Gallie, B. L. et al. Digital retinoblastoma documentation supports care and research. Can J Ophthalmol (2024). 
2. Alshahrani, N. O. et al. Single- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma. Am J Ophthalmol 269, 488-496 (2024). 
3. Tomar, A. S. et al. Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. Br J Ophthalmol 107, 127-132 (2023). 
4. Lando, L., Mallipatna, A., Kletke, S. N. & Gallie, B. Orbital Complications and Cost Analysis of Enucleation by Myoconjunctival versus Conventional Techniques for Retinoblastoma. Ocul Oncol Pathol 9, 123-129 (2023). 
5. Feng, Z. X., Zhao, J., Zhang, N., Jin, M. & Gallie, B. Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma. Invest Ophthalmol Vis Sci 64, 27 (2023). 

Funding

Dr. Gallie’s research is currently supported by external grants including:

• Uplifting Athletes - $49,489 USD
• After the Glow - $20,000 USD